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Abstract On 10 January 2020, a new coronavirus causing
a pneumonia outbreak spread rapidly in all of the World.
On 19 February 2020, the first official announcement of
death from 2019-Nov was made in Iran. As of 7 March
2020, there were 101,927 confirmed cases of Covid-19
infection, including 3486 deaths, reported in the World. In
the eastern and Mediterranean region Iran with 4747 con-
firmed cases of Covid-19 infection and 124 deaths, is in the
critical stage. Therefore, there is a matter of urgency
combating this new virus and stopping the epidemic. Here,
we focus on symptoms and the development of fast diag-
nosis methods, as well as potential management to prevent
or treat the Covid-19 infection.
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Introduction
One of the major causes of morbidity and mortality
worldwide is viruses [4, 7]. Coronaviruses (CoVs) belong
to the family Coronaviridae in the order Nidovirales and
they are enveloped, positive-sense, single-stranded RNA
viruses. They have the zoonotic origin and they are dis-
tributed broadly among humans and other animals like
mammals and birds, which cause respiratory, hepatic,
enteric, and neurologic diseases [13]. Two fatal
coronaviruses emerged periodically in the world in 2002
and 2012. The first one was severe acute respiratory syn-
drome coronavirus (SARSCoV) and the second one was
Middle East respiratory syndrome coronavirus (MERS-
CoV) [12].On 10 January 2020, the World Health Orga-
nization (WHO) identified the unknown pathogen as a
novel coronavirus denoted as Covid-19 or 2019-nCoV. On
19 February the first case was reported in Iran [14]. The
patient was found in the Kamkar-Arabnia Hospital of Qom,
a city located near Tehran [2]. Currently, Tehran, Qom, and
Mazandaran have the highest number of patients in Iran
and are in critical condition. However, no city has been
quarantined in Iran and this has led to an increasing number
of patients every day. As of 7 March 2020, there were
101,927 confirmed cases of Covid-19 infection, including
3486 deaths, reported in all of the world. In the eastern and
Mediterranean region, Iran with 4747 confirmed cases of
Covid-19 infection and 124 deaths, is in the critical stage
[15].
How did Covid-19 start in Iran?
Iranian authorities have put forward two theories for the
start of the 2019-nCoV in Iran. The first theory was an
Iranian airline flying many times to China at the Wuhan
2019-nCoV outbreak. The second theory was the return of
an Iranian businessman who had returned from china to
Qom with several flights [2]. Neither of these two theories




1 Student Research Committee (SRC), Faculty of Medicine,
Iran University of Medical Sciences (IUMS), Shahid Hemmat





Symptoms of Iranian Covid-19 patients
Due to the current epidemiological survey, most individ-
uals had a history of close contact with the 2019-nCoV
infected patient. The incubation period is commonly
3–7 days [16]. On January 2, 2020, Huang et al. [5], first
reported clinical features of 41 patients confirmed to be
infected with 2019-nCoV. The characteristics of Covid-19
infected patients in hospitals of Tehran, Iran are approxi-
mately the same as all of the world. New symptoms pre-
viously not known yet in the world has not seen in Iranian
patient until now. With the rise of cases worldwide, the
symptoms of the disease have been better characterized.
The symptoms of 2019-nCoV infection are nonspecific.
Fever, cough, dyspnea, myalgia or fatigue, sputum pro-
duction, headache, hemoptysis, and diarrhea are initial
Covid-19 symptoms. The most common symptoms are
onset fever, generalized weakness, and dry cough. Some
patients have headache and/or myalgia, but upper respira-
tory symptoms such as runny nose are rare [16]. Some
cases have Diarrhea, which had been reported 10.6% in
SARS and up to 30% in MERS [1]. Most of the patients
have shortness of breath. If the disease could not be con-
trolled, they might develop acute respiratory distress syn-
drome (ARDS), followed by septic shock, refractory
metabolic acidosis and coagulation dysfunction [16].
Covid-19 diagnosis by laboratory testing
In most cases total white blood cells, lymphocyte, and
platelet are lower than the average with extended activated
thromboplastin time, increased C-reactive protein and
muscle enzyme level. In the early days of the disease, these
symptoms are not detectable. In severe disease, the
D-dimer level is higher and lymphocyte decrease pro-
gressively and the cytokine storm such as IL1B, IL1RA,
IL7, IL8 can be associated with disease severity [5, 1]. On
chest CT scans, the multifocal ground glass changes are
typical of viral pneumonia. If the disease continued to
develop and in the bilateral multiple lobular and subseg-
mental areas of consolidation would be found on chest CT
scan. The lungs of elderly patients showed more diffuse
and extensive imaging than those of the younger patients
[5, 1].
In Iran, the government has stated that they can perform
three coronary tests per day, which are critical to screening
for coronavirus. These tests are appropriate in the early
days of the disease. But as the number of patients pro-
gresses, more tests will need to be done [2].
Vaccines and treatments
In vulnerable populations that are vulnerable to severe
damage, when Vaccines exposed to a particular pathogen
of interest, they can protect against disease and infection.
Several efforts to develop Covid-19 vaccines are under-
way, but the WHO and scientists estimate it will take one
to two years to be available and ready to use [10]. There are
already a number of vaccine candidates being developed
but most are still in the preclinical testing stage.
Although anti-inflammatory and antiviral treatments
have been employed present, at present in all of the world
and Iran, most treatment is symptomatic and supportive.
For complicated patients, supportive treatment has inclu-
ded continuous renal replacement therapy (CRRT), inva-
sive mechanical ventilation, and even extracorporeal
membrane oxygenation (ECMO).
There aren’t any specific antiviral drugs that confirmed
effective. Remdesivir [3], Ritonavir [9] and Baricitinib [11]
suggested as a potential drug for the Covid-19 treatment. A
new study conducted by the ‘‘front-line’’ medical providers
combating 2019-nCoV in China indicated that systemic
corticosteroid treatment didn’t show remarkable benefit
[8]. According to the searches we made at the Iranian
Registry of Clinical Trial (IRCT) [6], we found that no
studies have been conducted in Iran about 2019-nCoV so
far.
On March 1, 2020, Baqiyatallah Medical Sciences
University (BMSU) announce that they are developing
drugs and a vaccine for Covid-19. Three research groups in
BMSU were working on treatments for Covid-19, one of
the teams had already come up with a drug that could be
used to cure the illness and one of the drugs has passed
laboratory tests. Iranian researchers in BMSU also were
working on a human genetic material Covid-19 vaccine.
They hope that the human genetic material Covid-19
vaccine would be developed within less than 12 months to
help all of the world countries to prevent the spread of the
Covid-19 infection [2].
Although trials of vaccines and antivirals are underway,
treatment is mainly supportive and symptomatic. It is
important to inform the medical staff that they are at risk
and they should use protective measures. Healthcare pro-
viders and the government should follow subsequent
reports as the situation will likely change rapidly and
benefit from the results of new research.
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